PHD finger protein 5AGenealiases: INI · Rds3 · SAP14b · SF3B7 · SF3b14b · bK223H9.2
Q-omics provides the consensus-scored PHF5A profile across patient tissues and cancer cell-line models. PHF5A expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, PHF5A is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, PHF5A protein abundance shows 38,061 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, HNSC, and LSCC as cancer lineages where PHF5A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PHF5A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PHF5A survival associations across molecular data types. PHF5A RNA expression shows survival associations in the most cancer types (27), followed by mutation status (3) and mass-spec protein abundance (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PHF5A RNA expression–survival associations across cancer types. High PHF5A expression shows unfavorable associations in ACC, LIHC, UVM, LUAD and MESO, but favorable associations in READ. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for PHF5A RNA expression.
This table summarizes PHF5A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 9. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for PHF5A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PHF5A shows lower tumor expression in THCA and higher tumor expression in HNSC, LIHC, BLCA, COAD and STAD. The HNSC box plot shows higher PHF5A RNA expression in tumor versus normal tissue (log2 FC = +1.270, t-test p < 0.001).
This table shows molecular features associated with PHF5A in patient tissues and cancer cell lines. In patient samples, PHF5A shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, PHF5A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
